Skip to content

Research for the Clinical Effect and Immune Mechanism of Soothing the Lung and Anti-fever, Resolving Blood-stasis and Unblocking Collaterals in the Treatment of Mycoplasma Pneumoniae Pneumonia in Children

Research for the Clinical Effect and Immune Mechanism of Soothing the Lung and Anti-fever, Resolving Blood-stasis and Unblocking Collaterals in the Treatment of Mycoplasma Pneumoniae Pneumonia in Children

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022590
Enrollment
Unknown
Registered
2019-04-21
Start date
2019-05-01
Completion date
Unknown
Last updated
2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mycoplasma Pneumoniae Pneumonia

Interventions

Sponsors

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. Mycoplasma pneumoniae pneumonia in children meets the western medical diagnostic criteria; 2. Thermal process>48h and<96h; 3. The cough is prominent and persistent,and graded=2; 4. Peripheral white blood cell (WBC)count was normal; 5. It conforms to the TCM syndrome standard of wind-heat closed the lung or poison-heat closed the lung; 6. The children are aged 5~14; 7. The informed consent process is in compliance with regulations,the legal representative of the children signed the informed consent files.

Exclusion criteria

Exclusion criteria: 1. For children with severe pneumonia, segmental or lobar parenchymal infiltration shadow similar to that of bacterial pneumonia can be clearly diagnosed as bacterial pneumonia or viral pneumonia, and simple hilar lymphadenoma with large through the chest X-ray manifestations; 2. Those who have used macrolide antibiotics and hormones before enrollment; 3. Confirmed mycoplasma pneumoniae infection in the past 3 months; 4. Pulmonary complications, including pleural effusion or empyema, pneumothorax, pulmonary abscess, bronchopleural fistula, necrotizing pneumonia, and acute respiratory failure, have occurred; 5. Pulmonary infection caused by primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory tract malformation, abnormal lung development, aspiration pneumonia, lung malignancy and other basic diseases; 6. Patients with severe malnutrition, rickets and severe primary diseases of heart, brain, liver, kidney and hematopoietic system; 7. Allergic constitution (allergic to more than 2 kinds of substances), or allergic to macrolide antibiotics and components of jinzhen oral liquid; 8. According to the researcher's judgment, those who are not suitable for enrollment.

Design outcomes

Primary

MeasureTime frame
Clinical recovery time;Complete antipyretic time;Relieving time of cough and sputum cough;TCM syndrome effect;Complication rate;Saliva sIgA;Blood IgA;blood IgM;blood IgG;T cell subgroups;IL-10;IL-17;IL-18;NO;ROS;Arg-1;ADA;NF-kB;Intestinal sIgA;Intestinal flora;Intestinal environment;Alveolar lavage fluid proteomic analysis;Incidence of clinical adverse events/reactions;Blood routine;Urine routine;Liver function;Kidney function;Electrocardiogram;

Countries

China

Contacts

Public ContactLi Xinmin

Tianjin University of Traditional Chinese Medicine

tjtcmlxm@163.com+86 13902095399

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026